HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CORT 108297

a fused-ring azadecalin

Also Known As:

CORT108297

Networked: 5 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Aza Compounds: 3
  - CORT 108297: 5
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 4 or More Rings Heterocyclic Compounds
    - CORT 108297: 5

Experts

1.	Hunt, Hazel: 2 articles (01/2016 - 09/2014)
2.	Arafa, Salwa R: 1 article (01/2021)
3.	Danzer, Steve C: 1 article (01/2021)
4.	Gaitonde, Kevin D: 1 article (01/2021)
5.	Herman, James P: 1 article (01/2021)
6.	Kraus, Kimberly L: 1 article (01/2021)
7.	Packard, Benjamin A: 1 article (01/2021)
8.	Suru, Venkat: 1 article (01/2021)
9.	Wulsin, Aynara C: 1 article (01/2021)
10.	Bacalao, Maria A: 1 article (01/2017)

Related Diseases

1.	Weight Gain 06/01/2010 - "Increasing doses of CORT 108297 were associated with less weight gain." 06/01/2010 - "When vehicle was added to their olanzapine dose, they continued to gain weight; when CORT 108297 was added to their regimen, they lost a significant amount of weight. " 06/01/2010 - "Two experiments tested whether CORT 108297, a newly identified selective glucocorticoid antagonist could (i) reduce and (ii) prevent olanzapine-induced weight gain in rats. "
2.	Status Epilepticus (Complex Partial Status Epilepticus) 01/01/2021 - "The glucocorticoid receptor specific modulator CORT108297 reduces brain pathology following status epilepticus."
3.	Prostatic Neoplasms (Prostate Cancer) 01/01/2017 - "Furthermore, GR-regulated proliferation-associated genes AKAP12, FKBP5, SGK1, CEBPD, and ZBTB16 are inhibited by CORT108297 treatment in vivo Together, these data suggest that GR-selective nonsteroidal SGRMs potently inhibit GR activity and prostate cancer growth despite AR pathway inhibition, demonstrating the therapeutic potential of SGRMs in GR-expressing CRPC. " 01/01/2017 - "Here, we report that two novel nonsteroidal and highly selective GR modulators (SGRM), CORT118335 and CORT108297, have the ability to block GR activity in prostate cancer and slow CRPC progression. "
4.	Hypertrophy 09/01/2014 - "In a separate experiment employing control NFR/NFR mice, treatment with corticosterone for 5 days reduced DCX+ neuroblasts and induced astrocyte hypertrophy, whereas treatment with CORT108297 antagonized these effects. "
5.	Gliosis 09/01/2014 - "Normalization of neuronal progenitors, astrogliosis and microglial phenotype by CORT108297 indicates the usefulness of this antagonist to normalize hippocampus parameters of Wobbler mice. " 09/01/2014 - "After CORT108297 treatment, Wobblers showed diminished astrogliosis, and changed the phenotype of Iba1+ microglia from an activated to a quiescent form. "

Related Drugs and Biologics

1.	Glucocorticoids
2.	Glucocorticoid Receptors (Glucocorticoid Receptor)
3.	Peptides (Polypeptides)
4.	Corticosterone
5.	Amyloid (Amyloid Fibrils)
6.	Olanzapine (Zyprexa)
7.	CORT113176
8.	CORT118335